As I see it

Share this article:
The lower the FDA sinks in public esteem, the more it shows a bunker mentality, withdrawing into its shell and stalling on media inquiries. You know it's getting bad when the media complain in public (no reporter likes to tell readers he's been blocked). That happened in March when Cybercast News Service told its readers it had been thwarted by the FDA for two weeks in its efforts to get an interview about a contaminated blood product, including a promise to respond that was broken by an associate commissioner.

A few weeks earlier, a former editor with the American Public Health Association, Kathryn Foxhall, spoke for many journalists when she told the FDA's new Risk Communication Advisory Committee about effective “censorship” the agency practices by limiting access to, then monitoring interviews with, its officials—which has “a chilling effect.”

In its media management policies, the FDA prefers to deal with reporters who are unlikely to ask tough questions, mainly because they don't know enough to do so. This “dumbs down” the agency's public discourse, which, ultimately, can lead to accountability problems.

Then I received anonymously in the mail, apparently from a fearful FDA employee, an internal document, FDA Employee Guidelines for Safeguarding Non-Public Information. Its 10 pages of menacing text sweepingly defines “non-public information” as any info gained by reason of federal employment that has not already been made available to the public, and it threatens criminal penalties for disclosure. How, I wonder, is any employee expected to know what is already available to the public? 
So much for all those high-level promises to make this agency more “transparent” and accountable to the general public!

Dickinson is editor of Dickinson's FDA Webview (

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications